Recent news
October 2010
Prominent new study on HIV/AIDS financing calls for investments in research for new tools
October 13, 2010 -- A prominent new study published by the Results for Development Institute in the Lancet examines HIV/AIDS prevention and treatment financing through 2031. The study estimates the cost of four HIV/AIDS prevention and treatment scenarios and found that without a cure or vaccine for HIV, as much as $722 billion might be needed to fight the disease by 2031, one-third of which would be needed for Africa alone. “An important lesson from the aids2031 project is that everyone who is working to combat HIV/AIDS (governments, civil society, donors, and others) needs to focus on long-term trends and outcomes if we are to adopt the best policies today,” the study authors wrote, concluding, “Since the mid-1990s, we have often been preoccupied with the legitimate short-term challenges of achievement of large-scale political, social, and financial mobilization and rapid expansion of HIV/AIDS treatment. This work has yielded impressive results. However, our short-term outlook has caused us to lose sight of some of the key actions we need to take now to save money in the future, such as investment in research and development to generate game-changing technologies and intensification of targeted, cost-effective prevention.” See the links below for more details.
